U.S. Patent and Trademark Office, U.S. D. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it conta

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10595946
Filing Date		
First Named Inventor	Fran	cois Gueissaz
Art Unit		
Examiner Name		
Attornov Docket Numb	or.	ICB0352

	U.S.PATENTS								Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Date	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	6223586	B1	2001-05	5-01	Dierenbach et al.				
	2	4224565		1980-0	9-23	Sosniak et al.				
	3	4282744		1981-0	8-11	Dick				
	4	5307139		1994-04	4-26	Tyson et al.				
if you want to dee decisional o.o. I dean charlot information produce elect the Para Batton.						Add				
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant Relo				Lines where ges or Relevan
	1	20020096421	A1	2002-07	7-25	Cohn et al.				
If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or V	vhere Rel	or Relevant

| Application Number | 10995945 | Filing Date | Transcription | Transcription

1	1 310 380	EP EP	A1	2003-05-14	SensoNor asa	
2	0 874 379	EP	A1		Asulab S.A.	Z

If you wish to add additional Foreign Patent Document clation information please click the Add button Add NoN-ATENT LITERATURE DOCUMENTS Remove Click and the Add button Charles of the subtraction of the

middis	110	publisher, city and/or country where published.		
	1	International Search Report assued in corresponding application no. PCT/EP2004/012626 completed February 17, 2005 and mailed March 1, 2005.	Z	
	2	WAELTI, M. et al., "Package Quality Testing Using Integrated Pressure Sensor", 1998 International Symposium on Microelectronics, pp. 961-996		
	3	NESE, Martin et al., "New Method for Testing Hermeticity of Silicon Sensor Structures", The 8th International Conference on Solid-State Sensors and Actuators, and Eurosensors IX. 1995, pp. 260-262		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Knd Codes of USPTO Patent Documents at www.USPTO.0CV or MPEP 901.04. ² Enter office that resued the document, by the two-letter code (WIPO Standard ST 3). ³ For Japanese patent documents, the reducation of the year of the region of the regress and precede the senial number of the patent document. After office of the patent patent patent patent document under WIPO Standard ST 16 of possible. ³ Applicated is to please a document under WIPO Standard ST 16 of possible. ³ Applicated is to please a document under with patent patent

Application Number | 10596946 | Filing Date |

Attorney Docket Number

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-06-12
Name/Print	Joera-Uwe Szipi	Registration Number	31799

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S.231.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.